dr. (Matthijs) MM Versteegh
Business director Erasmus University of Rotterdam
- Location
- Burg. Oudlaan 50, Rotterdam
- Room
- J5-55
- versteegh@imta.eur.nl
‹ Back to overview
Profile
Matthijs Versteegh, PhD (Utrecht, The Netherlands, 1984) is business director at the institute for Medical Technology Assessment (iMTA) at Erasmus University of Rotterdam. Matthijs holds an undergraduate in health sciences, and a master (cum laude) in science & technology studies (Maastricht University). He obtained his PhD in health economics on quantifying quality of life for economic evaluations of health from Erasmus University of Rotterdam. After completing his PhD, Matthijs worked for consultancy firm Ecorys (Dutch office) on projects for the European Commission (DG SANCO), the World Health Organisation (in Moldova and Kazakhstan), the World Bank (in India) and large regional variation studies for the Dutch board of Health…
Matthijs Versteegh, PhD (Utrecht, The Netherlands, 1984) is business director at the institute for Medical Technology Assessment (iMTA) at Erasmus University of Rotterdam. Matthijs holds an undergraduate in health sciences, and a master (cum laude) in science & technology studies (Maastricht University). He obtained his PhD in health economics on quantifying quality of life for economic evaluations of health from Erasmus University of Rotterdam. After completing his PhD, Matthijs worked for consultancy firm Ecorys (Dutch office) on projects for the European Commission (DG SANCO), the World Health Organisation (in Moldova and Kazakhstan), the World Bank (in India) and large regional variation studies for the Dutch board of Health Insurance (Zorginstituut Nederland). Matthijs is a member of the EuroQoL research foundation and the ‘Jonge Zorgdenktank’.
- M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
- M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: 10.1016/j.socscimed.2016.07.043
- M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0
- M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
- M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: 10.1016/j.socscimed.2016.07.043
- M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0
- M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- M.M. Versteegh, A.E. Attema & C.A. Uyl - de Groot (2019). Is verlies winst? Stoppen met TNF-alfaremmers. Nederlands Tijdschrift voor Geneeskunde, 163:D3709. [go to publisher's site]
- M. Canoy, M.M. Versteegh, A.L. Bredenoord & M. Verweij (2018). De prijs van zorg op een goudschaaltje. Medisch Contact.
- M. Canoy, A.L. Bredenoord, M. Verweij & M.M. Versteegh (2018). Welke patiënten worden de dupe? NRC Handelsblad (print).
- M.M. Versteegh (2017). Vaar niet op deernis voor enkelen bij duur medicijn. NRC Handelsblad (print).
- P.H.M. van Baal, M. Perry-Duxbury, P.L.H. Bakx, M.M. Versteegh, E.K.A. van Doorslaer & W.B.F. Brouwer (2019). A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Economics, 28 (1), 87-100.
- W.B.F. Brouwer, P.H.M. van Baal, N.J.A. Van Exel & M.M. Versteegh (2019). When is it too expensive? Cost-effectiveness thresholds and health care decision making. The European Journal Of Health Economics, 20 (2), 175-180.
- M.M. Versteegh, A.E. Attema & C.A. Uyl - de Groot (2019). Is verlies winst? Stoppen met TNF-α-blokkers. Nederlands Tijdschrift voor Geneeskunde.
- M.M. Versteegh, I. Corro Ramos, N.C. Buyukkaramikli, A. Ansaripour, V.T. Reckers - Droog & W.B.F. Brouwer (2019). Severity-Adjusted Probability of Being Cost Effective. Pharmacoeconomics (Print). doi: 10.1007/s40273-019-00810-8 [go to publisher's site]
- A.A.H. de Hond, P.L.H. Bakx & M.M. Versteegh (2019). Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population. Social Science & Medicine, 222, 180-187. doi: 10.1016/j.socscimed.2018.12.028 [go to publisher's site]
- M. Gheorghe, R.J. Hoefman, M.M. Versteegh & J. van Exel (2019). Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool. Pharmacoeconomics (Print), 37 (1), 93-103. doi: 10.1007/s40273-018-0706-6
- P.H.M. van Baal, M.S. Perry-Duxbury, P.L.H. Bakx, M.M. Versteegh, E.K.A. van Doorslaer & W.B.F. Brouwer (2018). A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Economics, 28 (1), 87-100. doi: 10.1002/hec.3831
- S. de Groot, W.K. Redekop, M.M. Versteegh, S. Sleijfer, E. Oosterwijk, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2018). Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Quality of Life Research. doi: 10.1371/journal.pone.0177364
- W.B.F. Brouwer, P.H.M. van Baal, N.J.A. van Exel & M.M. Versteegh (2018). When is it too expensive? Cost-effectiveness thresholds and health care decision-making. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1000-4
- I. Corro Ramos, M.M. Versteegh, J.M. Koenders, G.C. Linssen, J. Meeder & M.P.M.H. Rutten - van Molken (2017). Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health. doi: 10.1016/j.jval.2017.05.013
- M.F. Jonker, A.E. Attema, B. Donkers, E.A. Stolk & M.M. Versteegh (2017). Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment. Health Economics, 26 (12), 1534-1547. doi: 10.1002/hec.3445
- M.M. Versteegh, S. Knies & W.B.F. Brouwer (2016). From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. Pharmacoeconomics (Print), 34 (11), 1071-1074. doi: 10.1007/s40273-016-0431-y
- M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0
- M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003
- M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: 10.1016/j.socscimed.2016.07.043
- D.T. Arnold, D. Rowen, M.M. Versteegh, A. Morley, C.E. Hooper & N.A. Maskell (2015). Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health and Quality of Life Outcomes, 13 (6). doi: 10.1186/s12955-014-0196-y
- S. de Groot, A.J. Rijnsburger, M.M. Versteegh, J.M. Heymans, S. Kleijnen, W.K. Redekop & I. Verstijnen (2015). Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers. BMJ Open, 5::e007241. doi: 10.1136/bmjopen-2014-007241
- M.M. Versteegh, A.E. Attema, M. Oppe, N. Devlin & E.A. Stolk (2013). Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. European Journal of Health Economics (HEPAC), 14 (1), 43-51. doi: 10.1007/s10198-013-0507-y
- A.E. Attema, M.M. Versteegh, M. Oppe, W.B.F. Brouwer & E.A. Stolk (2013). LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS. Health Economics, 22 (4), 376-392. doi: 10.1002/hec.2804
- A.E. Attema, Y. Edelaar-Peeters, M.M. Versteegh & E.A. Stolk (2013). Time trade-off: one methodology, different methods. European Journal of Health Economics (HEPAC), 14 (1), 53-64. doi: 10.1007/s10198-013-0508-x
- A.E. Attema & M.M. Versteegh (2013). Would you rather be ill now, or later? Health Economics, 22 (12), 1496-1506. doi: 10.1002/hec.2894
- B.M.F. Janssen, M. Oppe, M.M. Versteegh & E.A. Stolk (2013). Introducing the composite time trade-off: a test of feasibility and face validity. The European Journal Of Health Economics, 14, 5-13. doi: 10.1007/s10198-013-0503-2
- R. Crott, M.M. Versteegh & C.A. de Uyl-de Groot (2013). An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Quality of Life Research, 22 (5), 1045-1054. doi: 10.1007/s11136-012-0220-9.
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. Uyl - de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32 (4), 554-568. doi: 10.1177/0272989X11427761
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- C. de Sonneville-Koedoot, M.M. Versteegh & J.S. Yaruss (2011). Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A-D). Journal of Fluency Disorders, 36, 222-230. doi: 10.1016/j.jfludis.2011.03.002
- M.M. Versteegh, D. Rowen, J.E. Brazier & E.A. Stolk (2010). Mapping onto EQ-5D for patients in poor health. Health and Quality of Life Outcomes, 8 (141), 1-26. doi: 10.1186/1477-7525-8-141
- M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
- M.M. Versteegh (2014, april 10). Quality of Life in Economic Evaluations of Health. EUR (187 pag.) Prom./coprom.: prof.dr. W.B.F. Brouwer.
Business director
- University
- institute for Medical Technology Assessment (iMTA)
- School
- Erasmus University of Rotterdam
EuroQoL research foundation
- Role
- Member
- Obtained Wage
- no